The inaugural TCR-based Therapies Summit is dedicated to supercharging your TCR design, translation and manufacturing strategy for solid tumor success
CAR-T has provided life-saving therapy in hematological cancers, but is yet to show great efficacy in solid tumor indications. Could TCR-based therapies become our weapon of choice in solid tumor indications? This April, go where no CAR-T has gone before by harnessing nature's weapon against solid tumors; arm your TCR therapies against 'undruggable' indications to produce safe, efficacious and life-saving therapies.
Why It’s Time For TCR-based Therapies
“Hanson Wade’s CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area.”
Steffen Walter, Chief Scientific Office, Immatics US
A record number of trials entered the clinic in 2019 with 15 trials forecast to finish in 2020 and many more to yield results. With an annual growth rate of 23.1%, this trend does not appear to be slowing, so this timely TCR-based therapy meeting is a unique opportunity to analyse and discuss progress as results emerge at a critical point in TCR development.
The large number of companies entering the TCR space is testament to progress in the field. With a combined effort to overcome HLA restrictions, there is a bright future for the delivery of TCR-based therapies to wider patient populations and cancer indications.
“The TCR-based Therapies Summit will be a great forum to learn from and network with leading scientists and companies working to develop T cells as immunotherapy especially for solid tumors.”
Laurence Cooper, Chief Executive Officer, Ziopharm Oncology
How Will It Help You Deliver Best-In-Class TCR Therapies?
Join experts as they discuss the design, efficacy and clinical development of TCR therapeutics for solid tumor indications and beyond.
- Optimize your TCR therapy approach
- Explore novel combination strategies
- Arm your cells against the hostile tumor microenvironment
- Improve target selection and off-target validation
- Explore the future of manufacturing for next-generation TCRs
20+ Expert Speakers Include
Senior Director in Translational Medicine
Kite: A Gilead Company
Senior Director, Oncology Cell Therapy New Products
Chief Executive Officer
Chairman, Molecular Pharmacology
Memorial Sloan Kettering Cancer Center
Chief Scientific Officer
“TCR-based Therapeutics and their targets are the next frontier in expanding the scope of cancer immunotherapy by providing access to currently undruggable oncogenic proteins."
David A. Scheinberg, Chairman, Molecular Pharmacology, Memorial Sloan Kettering Cancer Center